Diets and nonalcoholic fatty liver disease: The good and the bad

Clinical Nutrition

Volumn 33, Issue 2, 2014, Pages 186-190

  Asrih, Mohamed ^a   Jornayvaz, François R ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Carbohydrates; Diet; Fats; Fatty acids; Insulin resistance; NAFLD

Indexed keywords

CARBOHYDRATE; FATTY ACID;

DIETARY INTAKE; DISEASE ASSOCIATION; FOOD COMPOSITION; HUMAN; LIPID COMPOSITION; MACRONUTRIENT; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRIENT CONCENTRATION; NUTRIENT CONTENT; PATHOPHYSIOLOGY; REVIEW; WEIGHT REDUCTION;

CARBOHYDRATES; DIET; FATS; FATTY ACIDS; INSULIN RESISTANCE; NAFLD;

ANIMALS; DIET; DIETARY CARBOHYDRATES; DIETARY FATS; DISEASE MODELS, ANIMAL; FATTY ACIDS; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIFE STYLE; LIVER; MOTOR ACTIVITY; OBESITY; WEIGHT LOSS;

EID: 84895508097     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2013.11.003     Document Type: Review

References (53)

1. Bellentani S., Scaglioni F., Marino M., Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Digestive Diseases 2010, 28(1):155-161.
2. Anstee Q.M., Targher G., Day C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature Reviews Gastroenterology & Hepatology 2013, 10(6):330-344.
3. Cheung O., Sanyal A.J. Recent advances in nonalcoholic fatty liver disease. Current Opinion in Gastroenterology 2010, 26(3):202-208.
4. Jornayvaz F.R., Shulman G.I. Diacylglycerol activation of protein kinase cepsilon and hepatic insulin resistance. Cell Metabolism 2012, 15(5):574-584. [Epub 2012/05/09].
5. Machado M., Marques-Vidal P., Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. Journal of Hepatology 2006, 45(4):600-606.
6. Gariani K., Philippe J., Jornayvaz F.R. Non-alcoholic fatty liver disease and insulin resistance: from bench to bedside. Diabetes & Metabolism 2013, 39(1):16-26.
7. Musso G., Cassader M., Rosina F., Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012, 55(4):885-904.
8. Jornayvaz F.R., Birkenfeld A.L., Jurczak M.J., Kanda S., Guigni B.A., Jiang D.C., et al. Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(14):5748-5752.
9. Jornayvaz F.R., Jurczak M.J., Lee H.Y., Birkenfeld A.L., Frederick D.W., Zhang D., et al. A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gain. American Journal of Physiology Endocrinology and Metabolism 2010, 299(5):E808-E815. [Epub 2010/09/03].
10. Camporez J.P., Jornayvaz F.R., Petersen M., Pesta D., Guigni B.A., Serr J., et al. Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology 2013, 154(9):3099-3109. [Epub 2013/06/13]. 10.1210/en.2013-1191.
11. Camporez J.P., Jornayvaz F.R., Lee H.Y., Kanda S., Guigni B.A., Kahn M., et al. Cellular mechanism by which estradiol protects female ovariectomized mice from high-fat diet-induced hepatic and muscle insulin resistance. Endocrinology 2013, 154(3):1021-1028.
12. Cantley J.L., Yoshimura T., Camporez J.P., Zhang D., Jornayvaz F.R., Kumashiro N., et al. CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 2013, 110(5):1869-1874.
13. Jornayvaz F.R., Lee H.Y., Jurczak M.J., Alves T.C., Guebre-Egziabher F., Guigni B.A., et al. Thyroid hormone receptor-alpha gene knockout mice are protected from diet-induced hepatic insulin resistance. Endocrinology 2012, 153(2):583-591.
14. Jurczak M.J., Lee A.H., Jornayvaz F.R., Lee H.Y., Birkenfeld A.L., Guigni B.A., et al. Dissociation of inositol-requiring enzyme (IRE1alpha)-mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out mice. The Journal of Biological Chemistry 2012, 287(4):2558-2567.
15. Birkenfeld A.L., Lee H.Y., Majumdar S., Jurczak M.J., Camporez J.P., Jornayvaz F.R., et al. Influence of the hepatic eukaryotic initiation factor 2alpha (eIF2alpha) endoplasmic reticulum (ER) stress response pathway on insulin-mediated ER stress and hepatic and peripheral glucose metabolism. The Journal of Biological Chemistry 2011, 286(42):36163-36170.
16. Birkenfeld A.L., Lee H.Y., Guebre-Egziabher F., Alves T.C., Jurczak M.J., Jornayvaz F.R., et al. Deletion of the mammalian INDY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in mice. Cell Metabolism 2011, 14(2):184-195.
17. Lee H.Y., Birkenfeld A.L., Jornayvaz F.R., Jurczak M.J., Kanda S., Popov V., et al. Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology 2011, 54(5):1650-1660.
18. Hebbard L., George J. Animal models of nonalcoholic fatty liver disease. Nature Reviews Gastroenterology & Hepatology 2011, 8(1):35-44.
19. Asrih M., Jornayvaz F.R. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. The Journal of Endocrinology 2013, 218(3):R25-R36. [Epub 2013/07/09].
20. Mouzaki M., Allard J.P. The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease. Journal of Clinical Gastroenterology 2012, 46(6):457-467. [Epub 2012/04/04].
21. Bedogni G., Bellentani S. Fatty liver: how frequent is it and why?. Annals of Hepatology 2004, 3(2):63-65.
22. Musso G., Gambino R., De Michieli F., Cassader M., Rizzetto M., Durazzo M., et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003, 37(4):909-916.
23. Toshimitsu K., Matsuura B., Ohkubo I., Niiya T., Furukawa S., Hiasa Y., et al. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 2007, 23(1):46-52.
24. Machado M.V., Ravasco P., Jesus L., Marques-Vidal P., Oliveira C.R., Proenca T., et al. Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet. Scandinavian Journal of Gastroenterology 2008, 43(1):95-102.
25. Assy N., Nassar F., Nasser G., Grosovski M. Olive oil consumption and non-alcoholic fatty liver disease. World Journal of Gastroenterology: WJG 2009, 15(15):1809-1815.
26. Masterton G.S., Plevris J.N., Hayes P.C. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2010, 31(7):679-692.
27. Storlien L.H., Kraegen E.W., Chisholm D.J., Ford G.L., Bruce D.G., Pascoe W.S. Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science 1987, 237(4817):885-888.
28. Levy J.R., Clore J.N., Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology 2004, 39(3):608-616.
29. Capanni M., Calella F., Biagini M.R., Genise S., Raimondi L., Bedogni G., et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Alimentary Pharmacology & Therapeutics 2006, 23(8):1143-1151.
30. Tanaka N., Sano K., Horiuchi A., Tanaka E., Kiyosawa K., Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. Journal of Clinical Gastroenterology 2008, 42(4):413-418.
31. Brownell K.D., Farley T., Willett W.C., Popkin B.M., Chaloupka F.J., Thompson J.W., et al. The public health and economic benefits of taxing sugar-sweetened beverages. The New England Journal of Medicine 2009, 361(16):1599-1605.
32. Malik V.S., Popkin B.M., Bray G.A., Despres J.P., Hu F.B. Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. Circulation 2010, 121(11):1356-1364.
33. Maersk M., Belza A., Stodkilde-Jorgensen H., Ringgaard S., Chabanova E., Thomsen H., et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. The American Journal of Clinical Nutrition 2012, 95(2):283-289.
34. Ouyang X., Cirillo P., Sautin Y., McCall S., Bruchette J.L., Diehl A.M., et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. Journal of Hepatology 2008, 48(6):993-999.
35. Stanhope K.L., Havel P.J. Fructose consumption: considerations for future research on its effects on adipose distribution, lipid metabolism, and insulin sensitivity in humans. The Journal of Nutrition 2009, 139(6):1236S-1241S.
36. Stanhope K.L., Schwarz J.M., Keim N.L., Griffen S.C., Bremer A.A., Graham J.L., et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. The Journal of Clinical Investigation 2009, 119(5):1322-1334.
37. Abdelmalek M.F., Suzuki A., Guy C., Unalp-Arida A., Colvin R., Johnson R.J., et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51(6):1961-1971.
38. Yamaguchi K., Yang L., McCall S., Huang J., Yu X.X., Pandey S.K., et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45(6):1366-1374.
39. Assy N., Nasser G., Kamayse I., Nseir W., Beniashvili Z., Djibre A., et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Canadian Journal of Gastroenterology = Journal canadien de gastroenterologie 2008, 22(10):811-816.
40. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., Webb M., Blendis L., Halpern Z., et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. Journal of Hepatology 2007, 47(5):711-717.
41. Abid A., Taha O., Nseir W., Farah R., Grosovski M., Assy N. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. Journal of Hepatology 2009, 51(5):918-924.
42. Samaha F.F., Iqbal N., Seshadri P., Chicano K.L., Daily D.A., McGrory J., et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. The New England Journal of Medicine 2003, 348(21):2074-2081.
43. Bisschop P.H., de Metz J., Ackermans M.T., Endert E., Pijl H., Kuipers F., et al. Dietary fat content alters insulin-mediated glucose metabolism in healthy men. The American Journal of Clinical Nutrition 2001, 73(3):554-559.
44. Johnston C.S., Tjonn S.L., Swan P.D., White A., Hutchins H., Sears B. Ketogenic low-carbohydrate diets have no metabolic advantage over nonketogenic low-carbohydrate diets. The American Journal of Clinical Nutrition 2006, 83(5):1055-1061.
45. Fung T.T., van Dam R.M., Hankinson S.E., Stampfer M., Willett W.C., Hu F.B. Low-carbohydrate diets and all-cause and cause-specific mortality: two cohort studies. Annals of Internal Medicine 2010, 153(5):289-298.
46. de Koning L., Fung T.T., Liao X., Chiuve S.E., Rimm E.B., Willett W.C., et al. Low-carbohydrate diet scores and risk of type 2 diabetes in men. The American Journal of Clinical Nutrition 2011, 93(4):844-850.
47. Cortez-Pinto H., Jesus L., Barros H., Lopes C., Moura M.C., Camilo M.E. How different is the dietary pattern in non-alcoholic steatohepatitis patients?. Clinical Nutrition 2006, 25(5):816-823.
48. Andersen T., Gluud C., Franzmann M.B., Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. Journal of Hepatology 1991, 12(2):224-229.
49. Weight cycling. National Task Force on the Prevention and treatment of obesity. JAMA: The Journal of the American Medical Association 1994, 272(15):1196-1202.
50. Lazo M., Solga S.F., Horska A., Bonekamp S., Diehl A.M., Brancati F.L., et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010, 33(10):2156-2163.
51. Petersen K.F., Dufour S., Befroy D., Lehrke M., Hendler R.E., Shulman G.I. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005, 54(3):603-608.
52. Sacks F.M., Bray G.A., Carey V.J., Smith S.R., Ryan D.H., Anton S.D., et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. The New England Journal of Medicine 2009, 360(9):859-873.
53. Westerbacka J., Lammi K., Hakkinen A.M., Rissanen A., Salminen I., Aro A., et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. The Journal of Clinical Endocrinology and Metabolism 2005, 90(5):2804-2809.